CoChat
Sign Up
Cited by 6Menopause: Health Impacts and TreatmentsPelvic floor disorders treatmentsSexual function and dysfunction studies

The DOI matches its Crossref record.

Effects of topical dehydroepiandrosterone therapy in women after pelvic organ prolapse surgery

Nowakowski, Łukasz, Gałczyński, Krzysztof, Dybowski, Michał, Typek, Rafał, Dawidowicz, Andrzej, Miotła, Paweł, Olcha, Piotr, Rechberger, Tomasz·2023·Menopause
DOI 10.1097/gme.0000000000002183
Open this paper in CoChat — free account

Abstract

OBJECTIVE: Pelvic organ prolapse (POP) occurs predominantly in postmenopausal women. Restoration of the proper estrogenization of vaginal mucosa is important in preoperative and postoperative treatment, increasing the effectiveness of this approach. The objective of this study was the development of intravaginal vaginal suppositories containing DHEA and comparison of the clinical effects of vaginal topical therapy with DHEA, estradiol, or antibiotic after POP surgery. METHOD: Nine types of vaginal suppositories containing 6.5 mg DHEA in different bases were prepared to find optimal formulation for the vaginal conditions. Ninety women referred for POP surgery were randomly assigned to one of three groups receiving topical treatment in the postoperative period (estradiol, DHEA, or antibiotic). On admission to hospital and during follow-up vaginal pH, vaginal maturation index and vaginal symptoms were assessed. RESULTS: Vaginal suppositories with the base made from polyethylene glycol 1,000 without surfactants characterized the highest percentage of the released DHEA. In women treated with topical estradiol or DHEA a significant decrease in the number of parabasal cells, increase in superficial and intermediate cells in the vaginal smears, decrease in vaginal pH, and reduction of vaginal symptoms were observed. CONCLUSIONS: The use of topical therapy with DHEA or the use of topical therapy with estradiol in the postoperative period were both shown to improve maturation index, vaginal pH, and vaginal symptoms. The benefits of topical therapy with DHEA after pelvic organ prolapse repair brings similar results as estradiol, without potential systemic exposure to increased concentrations of sex steroids above levels observed in postmenopausal women.

Overview

Integrity signals

Registry

Crossref · 10.1097/gme.0000000000002183

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 34

  1. 2020, Narrative review of the epidemiology, diagnosis and pathophysiology of pelvic organ prolapse, Int Braz J Urol, 46, 5, 10.1590/s1677-5538.ibju.2018.0581 · DOI
  2. 2021, Genitourinary Syndrome of Menopause, J Midwifery Womens Health, 66, 729, 10.1111/jmwh.13277 · DOI
  3. 2008, Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women, J Steroid Biochem Mol Biol, 111, 178, 10.1016/j.jsbmb.2008.06.003 · DOI
  4. 2020, A randomized clinical trial comparing vaginal laser therapy to vaginal estrogen therapy in women with genitourinary syndrome of menopause: The VeLVET Trial, Menopause, 27, 50, 10.1097/GME.0000000000001416 · DOI
  5. 2013, Histologic and cytologic effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial, Female Pelvic Med Reconstr Surg, 19, 34, 10.1097/SPV.0b013e318278cc40 · DOI
  6. 2014, Effects of preoperative local estrogen in postmenopausal women with prolapse: a randomized trial, J Clin Endocrinol Metab, 99, 3728, 10.1210/jc.2014-1216 · DOI
  7. 2011, Vaginal DHEA to treat menopause related atrophy: a review of the evidence, Maturitas, 70, 22, 10.1016/j.maturitas.2011.06.005 · DOI
  8. 2012, Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors, Arch Gynecol Obstet, 285, 1397, 10.1007/s00404-011-2181-6 · DOI
  9. 2008, Effects of intravaginal dehydroepiandrosterone on vaginal histomorphology, sex steroid receptor expression and cell proliferation in the rat, J Steroid Biochem Mol Biol, 109, 67, 10.1016/j.jsbmb.2007.09.023 · DOI
  10. 2005, Is dehydroepiandrosterone a hormone?, J Endocrinol, 187, 169, 10.1677/joe.1.06264 · DOI
  11. 2019, FIGO review of statements on use of synthetic mesh for pelvic organ prolapse and stress urinary incontinence, Int J Gynaecol Obstet, 147, 147, 10.1002/ijgo.12932 · DOI
  12. 2020, Cystocele repair by a light tension-free vaginal mesh: results after 6 years of follow-up, Prog Urol, 30, 367
  13. 2015, Vaginal estrogen use in postmenopausal women with pelvic floor disorders: systematic review and practice guidelines, Int Urogynecol J, 26, 3, 10.1007/s00192-014-2554-z · DOI
  14. 2019, Long-term anatomic and functional results of laparoscopic sacrocolpopexy: a prospective study, Int Urol Nephrol, 51, 795, 10.1007/s11255-019-02124-2 · DOI
  15. 2013, Complications of pelvic organ prolapse surgery and methods of prevention, Int Urogynecol J, 24, 1859, 10.1007/s00192-013-2177-9 · DOI
  16. 2019, Pharmacotherapy for the treatment of vaginal atrophy, Expert Opin Pharmacother, 20, 821, 10.1080/14656566.2019.1574752 · DOI
  17. 2005, Vaginal estrogen therapy and overactive bladder symptoms in postmenopausal patients after a tension-free vaginal tape procedure: a randomized clinical trial, Menopause, 12, 421, 10.1097/01.GME.0000148645.93603.62 · DOI
  18. 2010, The use of oestradiol therapy in postmenopausal women after TVT-O anti-incontinence surgery, Maturitas, 66, 101, 10.1016/j.maturitas.2010.01.020 · DOI
  19. 2013, Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens, J Steroid Biochem Mol Biol, 138, 359, 10.1016/j.jsbmb.2013.08.002 · DOI
  20. 2010, High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy, Gynecol Endocrinol, 26, 524, 10.3109/09513590903511547 · DOI
  21. 2021, Clinical manifestations and evaluation of postmenopausal vulvovaginal atrophy, Gynecol Endocrinol, 37, 740, 10.1080/09513590.2021.1931100 · DOI
  22. 2011, The pH of the vaginal environment and phase-contrast microscopy of cytological smears in women after menopause, Menopause Review/Przegld Menopauzalny, 10, 222
  23. 1997, Vaginal pH as a marker for bacterial pathogens and menopausal status, Am J Obstet Gynecol, 176, 1270, 10.1016/S0002-9378(97)70345-4 · DOI
  24. 1999, Vaginal ph and parabasal cells in postmenopausal women, Obstet Gynecol, 94, 700
  25. 1996, Efficacy of estrogen supplementation in the treatment of urinary incontinence, Obstet Gynecol, 88, 745, 10.1016/0029-7844(96)00281-5 · DOI
  26. 2008, Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial, Obstet Gynecol, 111, 67, 10.1097/01.AOG.0000296714.12226.0f · DOI
  27. 2011, Efficacy and safety of ultra-low-dose vagifem (10 mcg), Patient Prefer Adherence, 5, 571
  28. 2011, Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia, Climacteric, 14, 282, 10.3109/13697137.2010.535226 · DOI
  29. 1995, The vaginal epithelium in the postmenopause—cytology, histology and pH as methods of assessment, Maturitas, 21, 51, 10.1016/0378-5122(94)00863-3 · DOI
  30. 1993, Urinary incontinence and related urogenital symptoms in elderly women, Acta Obstet Gynecol Scand Suppl, 158, 1
  31. 2015, Dehydroepiandrosterone intra vaginal administration for the management of postmenopausal vulvovaginal atrophy, J Steroid Biochem Mol Biol, 145, 139, 10.1016/j.jsbmb.2014.09.003 · DOI
  32. 2018, Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance), Support Care Cancer, 26, 1335
  33. 2021, Effective prevention of recurrent UTIs with vaginal estrogen: pearls for a urological approach to genitourinary syndrome of menopause, Urology, 151, 31, 10.1016/j.urology.2020.05.058 · DOI
  34. 2012, Bacterial vaginosis – diagnostyka i leczenie, Przegl Menopauz, 5, 356

Cited by

Sorted by citations

Metadata

Authors
Nowakowski, Ł., Gałczyński, K., Dybowski, M., Typek, R., Dawidowicz, A., Miotła, P., Olcha, P., & Rechberger, T.
Affiliations
Medical University of Lublin (PL)
Corresponding author
Nowakowski, Łukasz
ORCID
Venue
Menopause
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2023-06
Volume
30
Issue
6
Pages
629-634
ISSN
1072-3714 (ISSN-L)
DOI
10.1097/gme.0000000000002183
OpenAlex
W4367671467
Cited by
6
References
0
Citations by year
2026: 3 · 2025: 3
FWCI
1.23
Type
journal article
Language
en
Open access
closed
Locations
  • Menopause The Journal of The North American Menopause Society (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
  • Health Sciences › Medicine › Urology › Pelvic floor disorders treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
Keywords
dehydroepiandrosterone, pelvic organ prolapse, vaginal suppositories, topical estrogen, estradiol, postmenopausal women, vaginal maturation index, vaginal pH, vaginal symptoms, polyethylene glycol base, postoperative care
MeSH terms
Anti-Bacterial Agents, Dehydroepiandrosterone, Estradiol, Female, Humans, Suppositories, Pelvic Organ Prolapse

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review